A variety of monoclonal antibodies reactive with colorectal tumour associated antigens have been described (Steplewski et al., 1982;Herlyn et al., 1979;Lindholm et al., 1983;Durrant et al., 1986a). However, one problem that needs to be solved before monoclonal antibodies can be used effectively for imaging or therapy is the heterogeneity of cell surface antigen expression on tumours (Durrant et al., 1986a;Brattain et al., 1981;Dexter et al., 1981 tissues (Embleton et al., 1981; Price et al., 1983a, b). It has been used extensively for colorectal tumour imaging (Farrands et al., 1982;Armitage et al., 1983) and linked to ricin A chain has been screened in a phase 1 clinical trial (Byers et al., 1989). 228 recognises carcinoembryonic antigen and not normal cross-reacting antigen. Its main normal reactivity is with secretory components of the gastrointestinal tract. It has also been shown to localise in tumours of colorectal cancer patients (Pimm et al., 1986). 161 antibody also recognises CEA but also cross-reacts with NCA. It therefore binds to a number of normal tissues, including liver and kidney tissues and would therefore be of limited clinical value. C14 recognises the Y haptenic blood group antigen which is expressed widely on colorectal cancers and adenomas (Lloyd et al., 1983;Brown et al., 1984;Abe et al., 1986; Durrant et al., 1986a, b;Ernst et al., 1986). Its main reactivity with normal tissues is restricted to secretory epithelial tissues in individuals who secrete blood group substances (Brown et al., 1984 Our results indicate that more colorectal cancers were recognised and the intensity of staining was increased by using combinations of monoclonal antibodies when compared to a single antibody.